证券代码：688192 证券简称：迪哲医药 公告编号：2026-011 迪哲（江苏）医药股份有限公司 关于提前归还临时补充流动资金的闲置募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至 2026 年 3 月 6 日，公司已提前归还临时补充流动资金的闲置募 集资金人民币 10,336.33 万元。 一、募集资金临时补充流动资金情况 迪哲（江苏）医药股份有限公司（以下简称"公司"）于2025年4月29日召开 了第二届董事会第十三次会议、第二届监事会第十一次会议，审议通过了《关于 使用部分闲置募集资金临时补充流动资金的议案》，同意公司根据募集资金投资 项目的资金使用计划及项目的建设进度，在确保不影响募集资金投资项目建设进 度的前提下，使用总额不超过60,000万元（含本数）的部分闲置募集资金临时补 充流动资金，并仅用于与主营业务相关的生产经营使用，使用期限自董事会审议 通过之日起不超过12个月，到期归还至募集资金专用账户。具体内容详见公司于 2025年4月30日在上海证券交易所（www.sse.c ...

证券日报网讯 2月27日，迪哲医药发布2025年度业绩快报公告称，公司2025年实现营业总收入80113.56 万元，同比增长122.60%。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 2月27日，迪哲医药发布公告称，华泰联合证券更换公司持续督导保荐代表人，蓝图先生 接替许超先生，与丁明明先生共同负责公司IPO及2023年度定增的持续督导，督导期至2027年12月31 日。 ...

迪哲医药表示，作为全球源创新药的研发公司，持续的研发投入是公司实现高质量发展的关键支撑，因 此对于创新药的持续研发投入是影响公司经营财务状况的主要因素之一。本报告期是公司两款产品纳入 国家医保的第一个会计年度，销售呈现快速放量，实现产品合计销售收入8.01亿元；随着产品陆续上 市，产品销售收入和销售推广费用将成为影响公司经营财务状况的主要因素。 北京商报讯（记者 丁宁）2月27日晚间，迪哲医药（688192）发布2025年度业绩快报显示，报告期内， 公司实现营业收入约为8.01亿元，同比增长122.6%；归属净利润为-7.63亿元，同比实现减亏。 ...

业绩快报显示，2025年，公司已获批的两款产品舒沃哲®（通用名：舒沃替尼片）和高瑞哲®（通用 名：戈利昔替尼胶囊）均已首次纳入国家医保药品目录，有助于大幅提升患者的可及性，同时公司加大 产品推广，积极扩大产品市场份额，对公司经营产生了积极影响。 北京商报讯（记者 王寅浩 宋雨盈）2月27日，迪哲医药发布2025年业绩快报，2025年度公司实现营业总 收入8.01亿元，同比增长122.6%；归属于母公司所有者的净亏损为7.63亿元，上年同期为8.46亿元。 ...

Core Viewpoint - DIZHE Pharmaceutical (688192.SH) reported a significant financial performance for the fiscal year 2025, with total revenue of 800 million yuan, but also recorded substantial losses in operating profit and net profit [1] Financial Performance - The company achieved total operating revenue of 800 million yuan for the year 2025 [1] - Operating profit was reported at -766 million yuan, indicating a loss [1] - The net profit attributable to the parent company was -763 million yuan [1] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, was -842 million yuan [1] Product Development and Market Impact - Continuous investment in research and development is crucial for the company's high-quality growth, particularly in the field of innovative drugs [1] - The reporting period marks the first accounting year for two of the company's products included in the national medical insurance, leading to rapid sales growth [1] - The combined sales revenue from these products reached 800 million yuan, highlighting the impact of product launches on the company's financial status [1]

证券代码：688192 证券简称：迪哲医药 公告编号：2026-010 迪哲（江苏）医药股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迪哲（江苏）医药股份有限公司（以下简称"公司"）于近日收到持续督导 保荐机构华泰联合证券有限责任公司（以下简称"华泰联合"）出具的《关于更 换迪哲（江苏）医药股份有限公司首次公开发行股票及 2023 年度向特定对象发 行 A 股股票持续督导保荐代表人的函》。 公司首次公开发行股票并于 2021 年 12 月 10 日在上海证券交易所科创板上 市，聘请了中信证券股份有限公司（以下简称"中信证券"）担任首次公开发行 股票并在科创板上市的保荐机构，中信证券指派丁元女士、彭浏用先生担任保荐 代表人，持续督导期至 2024 年 12 月 31 日止。 公司于 2023 年 3 月 24 日召开第一届董事会第十六次会议、于 2023 年 4 月 14 日召开 2022 年年度股东大会，审议通过了《2023 年度向特定对象发行 A 股 股票预案》等相关议案。 ...

Financial Performance - The company achieved total operating revenue of 801.14 million yuan in 2025, representing a 122.60% increase compared to the previous year[3] - The net loss attributable to the parent company was 763.31 million yuan, a reduction of 82.65 million yuan from the previous year's loss[7] - The company's total assets increased by 74.69% to 3.00 billion yuan, while equity attributable to the parent company surged by 568.16% to 1.29 billion yuan[3] - The weighted average return on net assets improved to -73.92%, up from -161.12% in the previous year, indicating a positive trend in financial performance[3] Research and Development - Research and development expenses for the year amounted to 855.61 million yuan, reflecting the company's commitment to innovation[8] - The company is actively expanding the application potential of its commercialized products, with ongoing clinical trials for Shuwozhe® and Gaoruizhe® in NSCLC[12] Product Development and Approval - The company successfully launched two products, Shuwozhe® and Gaoruizhe®, which were included in the national medical insurance directory, significantly enhancing patient accessibility[6] - Shuwozhe® received FDA approval for treating adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, marking a significant milestone in the company's product portfolio[9] - The company’s subsidiary obtained a drug production license, ensuring qualifications for future commercial production[12] Capital and Liquidity - The company raised 1.773 billion yuan through a private placement of shares, significantly boosting its liquidity and capital reserves[7]

迪哲医药发布业绩快报，2025年营业收入8.01亿元，同比增长122.60%。归属于母公司所有者的净利 润-7.63亿元，上年同期为-8.46亿元。报告期内，公司实现营业收入8.01亿元，较上年度增长122.60%。 2025年，公司已获批的两款产品舒沃哲®（通用名：舒沃替尼片）和高瑞哲®（通用名：戈利昔替尼胶 囊）均已首次纳入国家医保药品目录，有助于大幅提升患者的可及性，同时公司加大产品推广，积极扩 大产品市场份额，对公司经营产生了积极影响。 ...

Core Viewpoint - On February 23, a total of 34 listed companies had their restricted shares unlocked, with a total market value of approximately 19.007 billion yuan [1] Group 1: Restricted Share Unlocking Details - Luzhou Laojiao (000568) had 2.0425 million shares unlocked under equity incentive restrictions - AVIC Xi'an Aircraft Industry (000768) had 4.3606 million shares unlocked under equity incentive restrictions - Hubei Energy (000883) had 19.2779 million shares unlocked under equity incentive restrictions - Jining Pharmaceutical (000919) had 1.92 million shares unlocked under equity incentive restrictions - Guangji Pharmaceutical (000952) had 2.5209 million shares unlocked under equity incentive restrictions - China Software (600536) had 57,200 shares unlocked under equity incentive restrictions - Xinhua Medical (600587) had 1.7845 million shares unlocked under equity incentive restrictions - Baoxin Software (600845) had 10.2578 million shares unlocked under equity incentive restrictions - China Railway (601390) had 55.9338 million shares unlocked under equity incentive restrictions - China Communications Construction (601800) had 5.593 million shares unlocked under equity incentive restrictions - StarNet Ruijie (002396) had 2.8342 million shares unlocked under equity incentive restrictions - Lopuskin (002333) had 22.3212 million shares unlocked under A-share issuance to legal persons - Wanbangda (300055) had 33.6538 million shares unlocked under A-share issuance to legal persons - Hangyang Co., Ltd. (002430) had 5.2049 million shares unlocked under equity incentive restrictions - Taijia Co., Ltd. (002843) had 949,600 shares unlocked under equity incentive restrictions - Nanda Optoelectronics (300346) had 130,000 shares unlocked under equity incentive restrictions - Anhui Natural Gas (603689) had 2.5064 million shares unlocked under equity incentive restrictions - Zhongyan Dadi (003001) had 97,200 shares unlocked under equity incentive restrictions - Yuanxiang New Materials (301300) had 30.2983 million shares unlocked with extended lock-up period - Yidao Information (001314) had 88.6187 million shares unlocked under pre-issuance restrictions - Tongda Electric (603390) had 579,500 shares unlocked under equity incentive restrictions - Yangzhou Jinqiao (603307) had 50 million shares unlocked under pre-issuance restrictions - Aili Home (603221) had 2.29 million shares unlocked under equity incentive restrictions - Zhili Fang (301312) had 333,900 shares unlocked under equity incentive restrictions - Kuntai Co., Ltd. (001260) had 83.25 million shares unlocked under pre-issuance restrictions - Entropy Technology (301330) had 92.5223 million shares unlocked with extended lock-up period - Yatong Precision (603190) had 596,100 shares unlocked under pre-issuance restrictions - Sanwang Communication (688618) had 87,400 shares unlocked - Longxun Co., Ltd. (688486) had 30.6312 million shares unlocked - Dize Pharmaceutical (688192) had 991,100 shares unlocked - Haohan Depth (688292) had 57.5177 million shares unlocked - Haizheng Biomaterials (688203) had 78.5601 million shares unlocked - Diaomicro (688381) had 55.9536 million shares unlocked - Zhongrun Optics (688307) had 29.8507 million shares unlocked [1]